Relmada Therapeutics, Inc. (RLMD)

NASDAQ: RLMD · USD

$3.34

+0.13 (+4.0%)· Recorded snapshot

Market cap	356.3M
Net income (ttm)	-61.9M
EPS (ttm)	-$0.85
Shares out	106.7M
Volume	1,477,510
Beta	0.51

Market data

Price

Recent price action with selectable time range.

Financial snapshot

Net income (ttm): -61.9M
EPS (ttm): -$0.85
Market cap: 356.3M

Ticker	Name	Market cap	P/E	P/S	ROIC	5Y rev CAGR	1Y total return	Rating
EXAS	Exact Sciences Corp	—	—	—	—	—	—	Mantener

Calendar

Next earnings

Upcoming earnings date and setup when available.

Upcoming

DateLoading

Window—

EPS estimate—

Revenue estimate—

Sector percentile context

Refreshed 2026-10-28 19:55 UTC

Forward P/En/a

P25 n/aP50 n/aP75 n/a

Trailing P/En/a

P25 n/aP50 n/aP75 n/a

ROE-55.7

P25 n/aP50 n/aP75 n/a

ROIC-35

P25 n/aP50 n/aP75 n/a

Benchmarks · 1M

All RLMD indicators

Market & fundamental data

Available fields

177

Groups with data

Currency

USD

Showing 177 of 177 available metrics for this ticker.

Profile and market data

Ticker identity, listing, currency, market cap, and source dates.

Metric	Value
Amount currency	USD
CIK code	0001553643
Company name	Relmada Therapeutics, Inc.
Country	United States
Country code	US
CUSIP number	75955J402
Earnings date	2026-11-12
Earnings time	amc
Employees	17
Employees change	-3
Employees growth	-15%
Enterprise value	$138.5M
Exchange	NASDAQ
Financial currency	USD
Financial report date	2026-06-30
First seen	2026-05-09
Fiscal year end	December
Founded	2004
In index	RUSSELL2000
Industry	Biotechnology
Is primary listing	Yes
Is SPAC	No
ISIN number	US75955J4022
Last 10-K release date	2026-03-19
Last earnings date	2026-08-06
Last refreshed	2026-10-28
Last stock split date	2019-09-30
Last stock split type	Reverse
Market cap	$356.3M
Market cap category	Small-Cap
Next earnings date	2026-11-12
Options	Yes
Price	$3.34
Price currency	USD
Sector	Healthcare
SIC code	2834
Stock price date	2026-10-28
Symbol	RLMD
U.S. state	Florida
Website	https://www.relmada.com

Valuation

Multiples, yields, enterprise-value ratios, and valuation checks.

Metric	Value
Earnings yield	-25.31%
FCF / EV yield	-34.94%
FCF yield	-13.17%
P/B ratio	1.66x
Price / tangible book value	1.69x
Sector forward P/E	23.56x
Sector P/E	50.13x

Profitability

Margins, returns on capital, cash conversion, and quality metrics.

Metric	Value
Profit per employee	$-3.6M
ROA	-32.39%
ROA (5Y)	-54.95%
ROCE	-29.41%
ROE	-55.66%
ROE (5Y)	-96.82%
ROIC	-34.96%

Growth

Revenue, earnings, cash-flow, and forward growth indicators.

Metric	Value
EPS growth quarters	17
EPS growth years	4
Net income growth years	3
Revenue growth years	0

Financial statements

Income-statement and cash-flow amounts, totals and per share.

Metric	Value
EBIT	$-62.2M
EPS	$-0.85
FCF per share	$-0.43
Financing cash flow	$243.8M
Free cash flow	$-46M
Free cash flow minus SBC	$-60.7M
Investing cash flow	$-187.8M
Net cash flow	$10M
Net income	$-61.9M
Operating cash flow minus SBC	$-60.7M
Operating income	$-62.2M
Stock-based compensation	$14.7M

Financial strength

Debt, cash, solvency, accounting-quality, and balance-sheet signals.

Metric	Value
Book value per share	$1.94
Debt / equity	0
Long-term assets	$19,500
Long-term liabilities	$5.1M
Net cash (debt)	$217.7M
Net cash / market cap	62.33%
Net cash growth	955.95%
Net debt / equity	-1.05
Piotroski F-Score	2
Shareholders' equity	$206.6M
Tangible book value	$206.6M
Tangible book value per share	$1.94
Total assets	$219.1M
Total cash	$217.7M
Total debt	$0
Total liabilities	$12.5M
WACC	7.07%

Liquidity

Current-asset coverage and working-capital efficiency metrics.

Metric	Value
Current assets	$219M
Current liabilities	$7.4M
Current ratio	29.52
Net working capital	$-6.1M
Quick ratio	29.34
Working capital	$211.6M

Dividends and buybacks

Dividend yield, payout, buybacks, and shareholder-yield indicators.

Metric	Value
Buyback yield / dilution	-136.32%
Dividend yield	0%
Shareholder yield	-136.32%

Performance and technicals

Returns, volatility, beta, momentum, RSI, and moving-average context.

Metric	Value
10Y price change	-28.4%
10Y return CAGR	-3.29%
10Y total return	-28.4%
150-day SMA	$5.60
1D price change	4.05%
1M price change	-14.75%
1M total return	-14.75%
1W price change	-2.83%
1W total return	-2.83%
1Y price change	40.13%
1Y return CAGR	40.16%
1Y total return	40.13%
20-day SMA	$3.31
200-day SMA	$5.36
3M price change	-37.21%
3M total return	-37.21%
3Y price change	9.2%
3Y return CAGR	2.98%
3Y total return	9.2%
50-day SMA	$3.89
50-day SMA vs 200-day SMA	50under200
52-week high	$8.00
52-week high date	2026-05-06
52-week low	$2.15
52-week low date	2025-11-03
5Y price change	-85.8%
5Y return CAGR	-32.33%
5Y total return	-85.8%
6M price change	-53.56%
6M total return	-53.56%
All-time high	$80.00
All-time high date	2014-10-29
All-time low	$0.24
All-time low date	2025-03-03
Average true range (ATR)	$0.20
Average volume	1.6M
Beta (1Y)	0.25
Beta (2Y)	1.25
Beta (5Y)	0.51
Change from 52-week high	-58.25%
Change from 52-week low	55.35%
Change from all-time high	-95.92%
Change from all-time low	1,258.15%
Change from open	4.05%
Day's gap	0%
Dollar volume	$4.9M
High price	$3.35
Low price	$3.19
Monthly RSI	44.89
Open price	$3.21
Position in 52-week range	93.75%
Premarket change	0.62%
Premarket close	$3.21
Premarket price	$3.23
Previous close	$3.21
Price vs 150-day SMA	-41.68%
Price vs 20-day SMA	-1.42%
Price vs 200-day SMA	-39.1%
Price vs 50-day SMA	-16.09%
Relative volume	0.94
RSI	40.32
Sharpe ratio	0.73
Sharpe ratio (3Y)	0.69
Sharpe ratio (5Y)	0.34
Sortino ratio	1.6
Sortino ratio (3Y)	1.14
Sortino ratio (5Y)	0.55
Volume	1.5M
Weekly RSI	32.61
YTD price change	-32.4%
YTD total return	-32.4%

Ownership and float

Institutional, insider, float, short-interest, and share-count fields.

Metric	Value
Float	82.6M
Float percentage	77.47%
Shares change (QoQ)	29.77%
Shares change (YoY)	136.32%
Shares held by insiders	3.23%
Shares held by institutions	75.04%
Shares outstanding	106.7M
Short % of float	14.74%
Short % of shares	11.42%
Short ratio	10.6 days

Deeper analysis on RLMD

14 sections in the full report · jump straight to what you need

Forecast

Base and Bull forecast paths with report-date return framing.

→

Valuation

Fair-value bridge, DCF, owner earnings, and peer multiples.

→

Sensitivity

Cost-of-equity and terminal-growth stress table.

→

Risks

Kill scenarios, soft-pass flags, and downside catalysts.

→

Earnings

Next earnings setup and beat / inline / miss thresholds.

→

Position sizing

Entry, exit, conviction, and quarterly monitoring rules.

→

Financials

Revenue, margins, cash flow, and balance-sheet context.

→

Peers

Relative valuation and profitability against the cohort.

→

Moat

Economic-profit evidence and competitive advantage risk.

→

Industry cycle

Sector phase, capital cycle, and secular tailwinds.

→

Frequently asked questions

About this RLMD report

Is a complete RLMD research report available?

No complete published report is available for Relmada Therapeutics, Inc. (RLMD) on this page. Market-directory data, when present, is not a substitute for a validated stock analysis.

Relmada Therapeutics, Inc. (RLMD)

Price

Financial snapshot

Fair-value bridge

Latest news · RLMD

Valuation

Profitability

Balance sheet

Trading

Next earnings

Sector percentile context

All RLMD indicators

Profile and market data

Valuation

Profitability

Growth

Financial statements

Financial strength

Liquidity

Dividends and buybacks

Performance and technicals

Ownership and float

Deeper analysis on RLMD

Frequently asked questions